VivoSeq
Oncology

Primary Peritoneal Cavity Cancer

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Primary Peritoneal Cavity Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Gynecologic Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

14

clinical trials

Completed10 · 71%
Terminated3 · 21%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recruiting·MMayo Clinic·Phase 1/2·NCT05920798·40 enrolled
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT01716715·111 enrolled
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·MMayo Clinic·Phase 2·NCT02283658·20 enrolled
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·GGynecologic Oncology Group·Phase 2·NCT01720173·30 enrolled
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·—·Phase 2/3·NCT00075712·150 enrolled
Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·MMayo Clinic·Phase 1·NCT02111941·19 enrolled
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00132067·60 enrolled
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00217555
Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00217568
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·RRoswell Park Cancer Institute·Phase 1·NCT01536054·7 enrolled
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT00126542·35 enrolled
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00331422·7 enrolled
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00287859·5 enrolled
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Terminated·GGynecologic Oncology Group·Phase 2·NCT00006812

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)